Prediction of chronic lymphocytic leukaemia incidence in Germany and of patients ineligible for standard chemotherapy

Hematological Oncology
Nora EisemannAlexander Katalinic

Abstract

Chronic lymphocytic leukaemia (CLL) patients often remain asymptomatic for several years after diagnosis. When the disease becomes symptomatic or progressive, chemotherapy with fludarabine in combination with an anti-CD20 antibody (FCR) is recommended as standard therapy, except for patients with relevant comorbidity or with del(17p13) oder TP53 mutation. We predict the number of prevalent CLL patients in 2011-2020 who need first-line therapy but are ineligible for FCR treatment. The input parameters of the Markov model are the estimated total CLL incidence (based on German cancer registry data) and clinical data on disease progression and patient characteristics (obtained by a systematic literature research). Plausibility ranges for the estimation of the total CLL incidence are given by the following: (1) inclusion of small lymphocytic lymphoma and (2) an alternative handling of death-certificate-only cases. The number of patients ineligible for FCR treatment increases from approximately 1200 in 2011 to approximately 1450 in 2020. The inclusion of small lymphocytic lymphoma cases results in 10% higher estimates, the alternative handling of death-certificate-only cases in 8% lower estimates. Recently, several new and targeted a...Continue Reading

References

Jan 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E MontserratC Rozman
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M ExtermannL Balducci
Jul 11, 2002·Annals of Hematology·T Hamblin
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J KeatingHagop Kantarjian
Oct 19, 2007·British Journal of Haematology·Graça M DoresMartha S Linet
Feb 4, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Davide RossiGianluca Gaidano
Oct 24, 2009·Blood·John G Gribben
Jan 21, 2010·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Kaci Wilhelm, Daisy Yang
Jun 1, 2010·Haematologica·David OscierUNKNOWN Chronic Lymphocytic Leukaemia Working Group, UK National Cancer Research Institute
Nov 26, 2010·Blood Reviews·Michael Hallek, Natali Pflug
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G WierdaMichael J Keating
Dec 7, 2011·Cancer Control : Journal of the Moffitt Cancer Center·Sheetal Desai, Javier Pinilla-Ibarz
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Nicole SkoetzAndreas Engert
May 24, 2012·Deutsche medizinische Wochenschrift·C-M Wendtner
Oct 13, 2012·British Journal of Haematology·David OscierUNKNOWN British Committee for Standards in Haematology
Nov 24, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M GhielminiUNKNOWN Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma
Feb 2, 2013·Der Internist·S Stilgenbauer, M Hallek
Oct 10, 2013·Deutsche medizinische Wochenschrift·C Maurer, M Hallek

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.